The Global Expansion of "Commercial Access" and...

adicionou um novo artigo Health

2026-01-05 09:20:56 -

The Global Expansion of "Commercial Access" and Value-Based Pricing in the 2026 Adeno-associated Virus Vector-based Gene Therapy Sector

As we conclude early 2026, the "Commercial Maturity" of the gene therapy sector is evident in the new "Value-Based Pricing" (VBP) models. Because these "One-Time Treatments" can cost millions of dollars, in early 2026, insurers are paying manufacturers in "Installments" based on the "Ongoing Health" of the patient. If the "Gene Expression" drops below a certain level in year 3 or 5, the "Future...

0 Comentários 0 Compartilhamentos 203 Visualizações 0 Anterior